| Project/Area Number |
23659299
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Laboratory medicine
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
MATSUURA Eiji 岡山大学, 大学院・医歯薬学総合研究科, 教授 (20181688)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOBAYASHI Kazuko 岡山大学, 大学院・医歯薬学総合研究科, 助教 (20304298)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 分子イメージング / Immuno-Theranostics / がん / メソセリン / リポソーム |
|---|
| Research Abstract |
The present study was aimed to develop a monoclonal antibody-based probe for PET and drug delivery targeting mesothelin (MSLN) expressing cancer, through the application of immunoliposomes. A humanized monoclonalantibody was developed from a mouse monoclonal antibody against MSLN. We also started to develop its single-chain variable fragment (scFv). In vivo mouse PET imaging with 64Cu-lableld Fab fragment of anti-MSLN antibody showed faster tumor targeting than the case with 64Cu-labeled anti-MSLN IgG. Liposomes conjugated with humanized anti-MSLN antibody and labeled with Cy5.5 were taken into MSLN-expressing cultured cancer cells in an antibody-dependent manner.
|
